These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 33747510)

  • 41. Omalizumab protects against allergen- induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma.
    Zielen S; Lieb A; De La Motte S; Wagner F; de Monchy J; Fuhr R; Munzu C; Koehne-Voss S; Rivière GJ; Kaiser G; Erpenbeck VJ
    Int Arch Allergy Immunol; 2013; 160(1):102-10. PubMed ID: 22948442
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
    Nowak D
    Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-immunoglobulin E therapy with omalizumab for asthma.
    Hendeles L; Sorkness CA
    Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.
    Ledford D; Busse W; Trzaskoma B; Omachi TA; Rosén K; Chipps BE; Luskin AT; Solari PG
    J Allergy Clin Immunol; 2017 Jul; 140(1):162-169.e2. PubMed ID: 27826098
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-IgE antibodies for the treatment of asthma.
    Buhl R
    Curr Opin Pulm Med; 2005 Jan; 11(1):27-34. PubMed ID: 15591885
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
    Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
    Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
    Holgate S; Bousquet J; Wenzel S; Fox H; Liu J; Castellsague J
    Curr Med Res Opin; 2001; 17(4):233-40. PubMed ID: 11922396
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding.
    Klunker S; Saggar LR; Seyfert-Margolis V; Asare AL; Casale TB; Durham SR; Francis JN;
    J Allergy Clin Immunol; 2007 Sep; 120(3):688-95. PubMed ID: 17631952
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma.
    Bousquet J; Wenzel S; Holgate S; Lumry W; Freeman P; Fox H
    Chest; 2004 Apr; 125(4):1378-86. PubMed ID: 15078749
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study.
    Schreiber J; Schwab Sauerbeck I; Mailänder C
    Adv Ther; 2020 Jan; 37(1):353-363. PubMed ID: 31741282
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Omalizumab in asthma: an update on recent developments.
    Humbert M; Busse W; Hanania NA; Lowe PJ; Canvin J; Erpenbeck VJ; Holgate S
    J Allergy Clin Immunol Pract; 2014; 2(5):525-36.e1. PubMed ID: 25213045
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Omalizumab and IgE in the Control of Severe Allergic Asthma.
    Gon Y; Maruoka S; Mizumura K
    Front Pharmacol; 2022; 13():839011. PubMed ID: 35359867
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-IgE for the Treatment of Chronic Urticaria.
    Wedi B; Traidl S
    Immunotargets Ther; 2021; 10():27-45. PubMed ID: 33628747
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
    Chipps BE; Figliomeni M; Spector S
    Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized Comparative Clinical Study of First Global Omalizumab Biosimilar with Innovator Product in Moderate to Severe Persistent Asthma.
    Apsangikar P; Ghadge P; Naik M; Nair S
    J Assoc Physicians India; 2020 Dec; 68(12):61-65. PubMed ID: 33247645
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Omalizumab: a review of its use in patients with severe persistent allergic asthma.
    McKeage K
    Drugs; 2013 Jul; 73(11):1197-212. PubMed ID: 23812924
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Anti IgE antibodies for the treatment of difficult asthma].
    Humbert M; Tonnel AB
    Rev Mal Respir; 2005 Dec; 22(6 Pt 1):983-90. PubMed ID: 16222222
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.
    Casale TB; Condemi J; LaForce C; Nayak A; Rowe M; Watrous M; McAlary M; Fowler-Taylor A; Racine A; Gupta N; Fick R; Della Cioppa G;
    JAMA; 2001 Dec; 286(23):2956-67. PubMed ID: 11743836
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treating atopic asthma with the anti-IgE monoclonal antibody.
    D'Amato G
    Monaldi Arch Chest Dis; 2002 Apr; 57(2):117-9. PubMed ID: 12357840
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria.
    Giménez-Arnau A; Maurer M; Bernstein J; Staubach P; Barbier N; Hua E; Severin T; Joubert Y; Janocha R; Balp MM
    Clin Transl Allergy; 2022 Feb; 12(2):e12121. PubMed ID: 35218324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.